 Results from the phase 12 BRILLIANCE study using EDIT-101 in patients with LCA10 are expected in the second half of 2022. Editas was the clear winner with respect to Broad winning the patent dispute case over Crispr patents back in February of 2022; This could change with appeals and other courts. 